Tuesday, August 28, 2018 9:26:00 PM
Nonsense. . .36 or 52 weeks for the Methadone launch? This doesn't even come close to what Nasrat stated during the CC on August 11/2018.
"Unidentified Analyst
AND filings, now that Elite have approval for generic Percocet, how soon will you launch? And then, now that Elite has approval for Methadone, how soon would you launch?
Nasrat Hakim
The two parts are very different. For Methadone we intent to launch immediately within the next few weeks, because it’s a smaller product and we started the negotiation with Glenmark while back and already signed the contract. Percocet it’s a much bigger product. So the sales for Methadone, I believe the IMS status about $30 million to $40 million. And for Percocet it's in the hundreds of million, [500 million to 600 million]. So the volume becomes an issue anytime you need evolve and you need the partner that can handle those large quantities. So for Methadone we've already got locked in with the Glenmark and we'll forward within the next few weeks. For Percocet it's probably the next few months."
https://seekingalpha.com/article/4197842-elite-pharmaceuticals-inc-eltp-ceo-nasrat-hakim-q1-2019-results-earnings-call-transcript?part=single
He can still be "correct" if it launch's in 4 weeks or 36 weeks or 52 weeks need I continue ……
"Unidentified Analyst
AND filings, now that Elite have approval for generic Percocet, how soon will you launch? And then, now that Elite has approval for Methadone, how soon would you launch?
Nasrat Hakim
The two parts are very different. For Methadone we intent to launch immediately within the next few weeks, because it’s a smaller product and we started the negotiation with Glenmark while back and already signed the contract. Percocet it’s a much bigger product. So the sales for Methadone, I believe the IMS status about $30 million to $40 million. And for Percocet it's in the hundreds of million, [500 million to 600 million]. So the volume becomes an issue anytime you need evolve and you need the partner that can handle those large quantities. So for Methadone we've already got locked in with the Glenmark and we'll forward within the next few weeks. For Percocet it's probably the next few months."
https://seekingalpha.com/article/4197842-elite-pharmaceuticals-inc-eltp-ceo-nasrat-hakim-q1-2019-results-earnings-call-transcript?part=single
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
